Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CYCC

CYCC - Cyclacel Pharmaceuticals Inc Stock Price, Fair Value and News

$1.29-0.01 (-0.77%)
Market Closed

47/100

CYCC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

47/100

CYCC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.3

Target 3M

$1.31

Target 6M

$1.31

CYCC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CYCC Price Action

Last 7 days

-17.5%

Last 30 days

-7.0%

Last 90 days

-28.3%

Trailing 12 Months

-98.4%

CYCC RSI Chart

CYCC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CYCC Valuation

Market Cap

6.3M

Price/Earnings (Trailing)

-1.16

Price/Sales (Trailing)

66.54

EV/EBITDA

-0.66

Price/Free Cashflow

-1.04

CYCC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.3

Target 3M

$1.31

Target 6M

$1.31

CYCC Fundamentals

CYCC Revenue

Revenue (TTM)

95.0K

CYCC Earnings

Earnings (TTM)

-5.4M

Earnings Growth (Yr)

49.51%

Earnings Growth (Qtr)

25.04%

CYCC Profitability

EBT Margin

-4466.32%

Return on Equity

-76.65%

Return on Assets

-66.67%

Free Cashflow Yield

-96.39%

CYCC Investor Care

Shares Dilution (1Y)

7727.79%

Diluted EPS (TTM)

118.85

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250095.0K0
2024449.0K80.0K74.0K43.0K
2023000420.0K
20220000
20210000
20200000
20190000
2018000150.0K
20161.6M1.5M987.0K843.0K
20151.9M1.8M1.8M1.9M
20141.3M1.4M1.8M1.7M
2013281.0K519.0K790.0K1.1M
2012668.0K526.0K400.0K230.0K
2011258.8K405.5K552.3K699.0K
2010000112.0K
20090000
Get all data in R, Python etc through our Historical Stock Data APIs

About Cyclacel Pharmaceuticals Inc

CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
0
 CEO
 WEBSITEcyclacel.com
 SECTORHealthcare
 INDUSTRYBiotechnology

Cyclacel Pharmaceuticals Inc Frequently Asked Questions

CYCC is the stock ticker symbol of Cyclacel Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Cyclacel Pharmaceuticals Inc is 6.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CYCC's fair value in chart for subscribers.

The fair value guage provides a quick view whether CYCC is over valued or under valued. Whether Cyclacel Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Cyclacel Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYCC.

As of Tue Jan 27 2026, CYCC's PE ratio (Price to Earnings) is -1.16 and Price to Sales (PS) ratio is 66.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYCC PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Cyclacel Pharmaceuticals Inc has provided -0.709 (multiply by 100 for percentage) rate of return.